secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001213900-23-038758
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron Q1 loss $4.6M, cash $13.7M; CFO resigns; HLHS survival 100% at 5 yrs
-------------------------------------------------------------------------------

- Net loss widened to $4.6M ($0.22/share) in Q1 2023 from $3.5M ($0.17/share) in Q1 2022.
- Cash and marketable securities fell to $13.7M at March 31, 2023 from $19.6M at Dec 31, 2022.
- CFO James Clavijo resigning effective June 9, 2023; external search for replacement ongoing.
- ELPIS I HLHS trial shows 100% survival up to 5 years vs historical 20% mortality for Lomecel-B.
- Topline results from CLEAR MIND Phase 2a Alzheimer's trial expected by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390023038758/0001213900-23-038758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390023038758/ea178436-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-038758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer